sigvotatug vedotin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for sigvotatug vedotin comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung. Most recent publication: Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design., Future Oncol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.
    Reck M, Lu S, O'Byrne KJ, et al. · Future Oncol · 2025
    PubMed: PMID 41388832 · NCT06758401 (Be6A Lung-02) · Carcinoma, Non-Small-Cell Lung
  2. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.
    Lyon RP, Jonas M, Frantz C, et al. · Mol Cancer Ther · 2023
    PubMed: PMID 37619980 · NCT04389632 · Carcinoma, Non-Small-Cell Lung

Publications by year

2023–2025: 2 publications.

2023
1
2025
1

Publications by indication

Carcinoma, Non-Small-Cell Lung (2)

  • Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.
    Future Oncol · 2025 · PMID 41388832 · NCT06758401
  • SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.
    Mol Cancer Ther · 2023 · PMID 37619980 · NCT04389632

Publications by journal

  • Future Oncol1 paper
  • Mol Cancer Ther1 paper

All sigvotatug vedotin publications (2)

2025 (1 paper)

  1. Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.
    Reck M, Lu S, O'Byrne KJ, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 41388832 · NCT06758401 (Be6A Lung-02) · Carcinoma, Non-Small-Cell Lung

2023 (1 paper)

  1. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.
    Lyon RP, Jonas M, Frantz C, et al. · Mol Cancer Ther · 2023 · Derived
    PubMed: PMID 37619980 · NCT04389632 · Carcinoma, Non-Small-Cell Lung

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 02 Jun 2026 16:16:04 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).